Skip to main content
Holly J. Meany on Muck Rack

Holly J. Meany

As seen in: Nature, Frontiers
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Holly J.

Contact Holly J., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial

|
By Stephanie Gomez, Ashley E. Geiger, Melanie Grant, Chase D. McCann, Jay Tanna, Anqing Zhang, Patrick Hanley, Jennifer Webb, Lindsay B. Kilburn, Brian Rood, Adriana Fonseca, Holly J. Meany, L. Vezina, Roger J. Packer, Catherine M Bollard, Eugene Hwang, Rachel A. DiCioccio, Anushree Datar, Divyesh Kukadiya, Fahmida Hoq, Conrad Russell Y. Cruz
| Nature Verified
Abstract Central nervous system (CNS) tumors are the deadliest cancers in children, highlighting the need for new therapies. The tumor-associated antigens (TAAs) WT1, PRAME and survivin are widely expressed by these tumors, and a manufacturing technique has been developed to target these intracellular TAAs using autologous, nongenetically engineered T cells.
Open in Who Shared Issue with article?

Treatment of extracranial rhabdoid tumor with intensive ifosfamide-containing chemotherapy regimens

|
By Jillian Smith Verified, Liny John, AeRang Kim, Amy B. Hont, Amy K. Frantz, Jeffrey S. Dome, Holly J. Meany
| Frontiers
Abstract Introduction: Extracranial malignant rhabdoid tumors (MRT) and rhabdoid tumors of the kidney (RTK) are rare pediatric solid tumors characterized by aggressive behavior and poor prognosis. Case reports have demonstrated successful outcomes using ifosfamide-containing chemotherapy regimens, leading some clinicians to incorporate this alkylating agent into treatment plans. We assessed our institutional experience treating MRT and RTK using ifosfamide-containing regimens.
Open in Who Shared Issue with article?
See all 2 articles